Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181870 · ClinicalTrials.gov registry record · Phase 4
Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder
A Phase 4 study of Bipolar Disorder and Mania, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT00181870: Completed Phase 4 study of Bipolar Disorder and Mania, sponsored by Massachusetts General Hospital.
NCT00181870 is a Phase 4 study of Bipolar Disorder and Mania that has completed, run by Massachusetts General Hospital. The registered enrollment target is 33 participants, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00181870, a Phase 4 study of Bipolar Disorder and Mania, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. The main goal of this study is to begin to address the void of information on safety, tolerability and effectiveness of Equetro in the treatment of Pediatric Bipolar Disorder.
Conditions Studied
Interventions
- DRUG carbamazepine ER (Equetro)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2005-07 |
| Phase | Phase 4 |
What the finished NCT00181870 record still lists
NCT00181870 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 332-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which carbamazepine ER (Equetro) is the first listed.
NCT00181870 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00181870 about?
NCT00181870 is a clinical study titled "Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder". This is an open-label pilot study of up to 1200 mg/day of carbamazepine ER (Equetro) in the treatment of children who meet DSM-IV criteria for Bipolar I, Bipolar II, or Bipolar Spectrum Disorder. The main goal of this study is to begin to address the void of information on safety, tolerability and e...
What is the current status of trial NCT00181870?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2005-07.
What conditions does trial NCT00181870 study?
This clinical trial studies the following conditions: Bipolar Disorder, Mania.
What interventions are being tested in trial NCT00181870?
The interventions under investigation include: carbamazepine ER (Equetro) (DRUG).
Who is sponsoring clinical trial NCT00181870?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181870 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00181870's enrollment target sits among peer trials
33 132nd of 162 higher than 30 of 162 other Bipolar Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bipolar Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
FMRI Study of Brain Response Before and After Lithium Treatment in People With Bipolar Disorder
COMPLETED · Phase 4
-
Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study
COMPLETED · Phase 4
-
Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
COMPLETED · Phase 4
-
Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence
COMPLETED · Phase 4
-
Lamictal As Add on Treatment in Mixed States of Bipolar Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia